Although post-operative weight loss outcomes associated with using other AOMs before bariatric surgery have not been assessed, other AOMs should still be considered if phentermine/topiramate is contraindicated or if an obesity-associated co-morbidity can be concomitantly addressed (e.g., GLP-1-RA in a patient with obesity and diabetes). This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.